Type 2 DM as monotherapy or in dual combination w/ metformin, a sulphonylurea or a thiazolidinedione in patients w/ insufficient glycaemic control; or in triple combination w/ a sulphonylurea & metformin when diet & exercise + dual therapy w/ these agents do not provide adequate glycaemic control; or in combination w/ insulin (w/ or w/o metformin) when diet & exercise & a stable dose of insulin do not provide adequate glycaemic control.
Monotherapy or combination therapy w/ metformin, thiazolidinedione, metformin + sulphonylurea, insulin 100 mg in 2 divided doses in the morning & evening. Combination therapy w/ sulphonylurea 50 mg once daily in the morning.
Should not be used in type 1 diabetes or diabetic ketoacidosis. End-stage renal disease on haemodialysis, renal impairment. Hepatic impairment. Perform liver function test prior to & during treatment at 3-mth intervals during the 1st yr & periodically thereafter. Discontinue use if AST/ALT ≥3 x ULN persists, or if jaundice & pancreatitis develop. Cardiac failure (NYHA class III-IV). Monitor for skin disorders eg, blistering & ulceration. Risk of developing acute pancreatitis; hypoglycaemia. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Pregnancy & lactation.
Sign Out
